Bio-Rad Laboratories, Inc. (BIO)

Market Cap	13.67B
Revenue (ttm)	2.80B
Net Income (ttm)	-6.03B
Shares Out	29.24M
EPS (ttm)	-201.41
PE Ratio	n/a
Forward PE	28.01
Dividend	n/a
Ex-Dividend Date	n/a

Volume	167,195
Open	466.43
Previous Close	464.26
Day's Range	456.67 - 470.92
52-Week Range	344.63 - 670.62
Beta	0.90
Analysts	Buy
Price Target	602.82 (+28.96%)
Earnings Date	Feb 16, 2023

About BIO

Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics,...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1952
• Employees: 8,200
• Stock Exchange: NYSE
• Ticker Symbol: BIO

Financial Performance

In 2021, BIO's revenue was $2.92 billion, an increase of 14.81% compared to the previous year's $2.55 billion. Earnings were $4.25 billion, an increase of 11.55%.

Analyst Forecast

According to 10 analysts, the average rating for BIO stock is "Buy." The 12-month stock price forecast is $602.82, which is an increase of 28.96% from the latest price.

Price Target

$602.82

(28.96% upside)

Analyst Consensus: Buy